Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.39)
# 290
Out of 5,182 analysts
242
Total ratings
44.1%
Success rate
26.27%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Downgrades: Neutral | $123 → $53 | $52.75 | +0.47% | 7 | Apr 6, 2026 | |
| ADMA ADMA Biologics | Downgrades: Neutral | n/a | $10.93 | - | 10 | Mar 26, 2026 | |
| RNAC Cartesian Therapeutics | Upgrades: Overweight | $16 | $7.07 | +126.31% | 1 | Mar 9, 2026 | |
| QURE uniQure | Upgrades: Neutral | $55 → $9 | $17.90 | -49.72% | 11 | Mar 2, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $153 → $125 | $68.85 | +81.55% | 10 | Feb 17, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Maintains: Overweight | $11 → $19 | $7.21 | +163.52% | 2 | Jan 15, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | $21 → $15 | $14.49 | +0.07% | 8 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $20.39 | +135.41% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $7.72 | +210.88% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $5.63 | +237.78% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $24 | $9.81 | +144.65% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $38 | $30.51 | +24.55% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $63 | $49.33 | +27.71% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $23.99 | +337.68% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $69.22 | +70.47% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $54.02 | +36.99% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $7.50 | +113.33% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $35.10 | -14.53% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $20.98 | +286.08% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $6.46 | +8.36% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $4.21 | +2,037.77% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.28 | +2,398.22% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $33.66 | +99.05% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.10 | +314.63% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.91 | +318.85% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.65 | +315.09% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.34 | +237.08% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.06 | +1,220.75% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $0.81 | +1,513.10% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.21 | +1,635.54% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.55 | +287.10% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.29 | +6,917.54% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $7.91 | +190.77% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $0.76 | +118,321.05% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $1.71 | +4,870.76% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $7.97 | +2,158.47% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.54 | +11,588.31% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.70 | +547.06% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.45 | +4,037.93% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $0.78 | +11,436.98% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.62 | +403,810.88% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $1.02 | +297,939.22% | 1 | Jan 9, 2020 |
Soleno Therapeutics
Apr 6, 2026
Downgrades: Neutral
Price Target: $123 → $53
Current: $52.75
Upside: +0.47%
ADMA Biologics
Mar 26, 2026
Downgrades: Neutral
Price Target: n/a
Current: $10.93
Upside: -
Cartesian Therapeutics
Mar 9, 2026
Upgrades: Overweight
Price Target: $16
Current: $7.07
Upside: +126.31%
uniQure
Mar 2, 2026
Upgrades: Neutral
Price Target: $55 → $9
Current: $17.90
Upside: -49.72%
Disc Medicine
Feb 17, 2026
Maintains: Overweight
Price Target: $153 → $125
Current: $68.85
Upside: +81.55%
Eupraxia Pharmaceuticals
Jan 15, 2026
Maintains: Overweight
Price Target: $11 → $19
Current: $7.21
Upside: +163.52%
Amicus Therapeutics
Dec 19, 2025
Downgrades: Neutral
Price Target: $21 → $15
Current: $14.49
Upside: +0.07%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $20.39
Upside: +135.41%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $7.72
Upside: +210.88%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $5.63
Upside: +237.78%
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $9.81
Upside: +144.65%
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $30.51
Upside: +24.55%
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $49.33
Upside: +27.71%
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $23.99
Upside: +337.68%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $69.22
Upside: +70.47%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $54.02
Upside: +36.99%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $7.50
Upside: +113.33%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $35.10
Upside: -14.53%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $20.98
Upside: +286.08%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $6.46
Upside: +8.36%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $4.21
Upside: +2,037.77%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.28
Upside: +2,398.22%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $33.66
Upside: +99.05%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $4.10
Upside: +314.63%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $1.91
Upside: +318.85%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.65
Upside: +315.09%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.34
Upside: +237.08%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.06
Upside: +1,220.75%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $0.81
Upside: +1,513.10%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.21
Upside: +1,635.54%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.55
Upside: +287.10%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.29
Upside: +6,917.54%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $7.91
Upside: +190.77%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $0.76
Upside: +118,321.05%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $1.71
Upside: +4,870.76%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $7.97
Upside: +2,158.47%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.54
Upside: +11,588.31%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.70
Upside: +547.06%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.45
Upside: +4,037.93%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $0.78
Upside: +11,436.98%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.62
Upside: +403,810.88%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $1.02
Upside: +297,939.22%